The SPDR S&P Biotech ETF (XBI) closed at $162.36 on September 1, 2026, slipping 0.02% over the past 24 hours as trading in the biotech sector remained subdued to start the month.
Over the trailing seven days, XBI has declined 1.11%, reflecting modest near-term pressure after a period of sustained strength. Despite the recent softening, the fund continues to hold onto substantial gains from the prior month.
The 30-day change stands at 9.76%, marking a notable stretch of outperformance for the ETF and its underlying basket of biotechnology stocks. That monthly advance represents one of the more significant moves in the fund's recent trading history.
Market capitalization data for XBI was not available at the time of publication. The fund tracks an equal-weighted index of biotechnology companies listed on the S&P Total Market Index.
